Anzeige
Mehr »
Donnerstag, 09.10.2025 - Börsentäglich über 12.000 News
Kursrakete 2025: CiTech präsentiert sich u.a. mit DroneShield neben Palantir & Rheinmetall - welche News sind zu erwarten?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1W5SA | ISIN: US9224751084 | Ticker-Symbol: VEE
Tradegate
09.10.25 | 16:06
258,40 Euro
-0,42 % -1,10
Branche
Software
Aktienmarkt
Sonstige
1-Jahres-Chart
VEEVA SYSTEMS INC Chart 1 Jahr
5-Tage-Chart
VEEVA SYSTEMS INC 5-Tage-Chart
RealtimeGeldBriefZeit
260,20260,9017:28
259,80261,3017:28
PR Newswire
162 Leser
Artikel bewerten:
(0)

Veeva Systems: Biopharma Leaders Advance the Future of Life Sciences at Veeva Commercial Summit Europe

Industry gathers to explore Veeva AI innovations and exchange ideas with companies including Astellas, Bayer AG, Boehringer Ingelheim, LEO Pharma, Moderna, and MSD

BARCELONA, Spain, Oct. 9, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Astellas, Bayer AG, Boehringer Ingelheim, LEO Pharma, Moderna, and MSD are among the key speakers at Veeva Commercial Summit, Europe, on 5-6 November in Madrid, Spain. The event brings together life sciences leaders to share experiences and ideas that advance commercial excellence across the industry.

Veeva Systems

Customers will learn about software and data innovations in Veeva Commercial Cloud, including Vault CRM Suite, the next-generation CRM suite, and Veeva Data Cloud. The event will also showcase how Veeva AI Agents for Vault CRM - Pre-call Agent, Content Agent, Free Text Agent, and Voice Agent - improves field productivity and customer engagement. Moderna will share how Veeva AI for PromoMats Quick Check Agent speeds content reviews before medical, legal, and regulatory (MLR) approval.

More than 100 sessions that spark new ideas to set future direction, will include:

Connecting sales, marketing, and medical for coordinated customer engagement

  • Bayer AG and Otsuka Europe discuss how a single customer view with embedded data connects functions and helps improve engagement.
  • LEO Pharma shares how it uses data on HCP preferences to understand the expectation-experience gap and drive more aligned and impactful customer interactions.
  • Bayer AG demonstrates how it is evolving go-to-market strategies with the next-generation CRM suite to increase customer centricity.

Establishing a strong data foundation for deeper customer insights

  • MSD discusses how deep KOL data and flexible workflows improve KOL engagement.
  • Bayer AG highlights how it has solidified its global data foundation with standardized HCP and HCO data to scale AI and achieve better commercial outcomes.

Accelerating the content lifecycle for more effective interactions

  • Astellas shows the path from fragmented planning and execution to unified content strategies with integrated technologies.

"Veeva Summit brings together leaders eager to explore fresh ideas and innovations, such as agentic AI, to help get medicines to the right patients faster. These insights and best practices strengthen the community's collective knowledge and drive meaningful progress across the industry," said Chris Moore, president of Veeva Europe.

As one of Europe's largest gatherings of life sciences leaders, the Veeva Commercial Summit brings together over 1,200 industry experts. The event is open exclusively to life sciences professionals. Register and review the agenda at veeva.com/eu/Summit.

About Veeva Systems
Veeva delivers the industry cloud for life sciences with software, data, and business consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu.

Veeva Forward-Looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended July 31, 2025, which you can find here (a summary of risks which may impact our business can be found on pages 33 and 34), and in our subsequent SEC filings, which you can access at sec.gov.

Contact:

Meera Lakhani-Patel
Veeva Systems
meera.lakhani-patel@veeva.com

Logo - https://mma.prnewswire.com/media/1488285/Veeva_Systems_Logo_v2.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/biopharma-leaders-advance-the-future-of-life-sciences-at-veeva-commercial-summit-europe-302579466.html

© 2025 PR Newswire
Epische Goldpreisrallye
Der Goldpreis hat ein neues Rekordhoch überschritten. Die Marke von 3.500 US-Dollar ist gefallen, und selbst 4.000 US-Dollar erscheinen nur noch als Zwischenziel.

Die Rallye wird von mehreren Faktoren gleichzeitig getrieben:
  • · massive Käufe durch Noten- und Zentralbanken
  • · Kapitalflucht in sichere Häfen
  • · hohe Nachfrage nach physisch besicherten Gold-ETFs
  • · geopolitische Unsicherheit und Inflationssorgen

Die Aktienkurse vieler Goldproduzenten und Explorer sind in den vergangenen Wochen regelrecht explodiert.

Doch es gibt noch Titel, die Nachholpotenzial besitzen. In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Goldaktien jetzt besonders aussichtsreich sind und warum der Aufwärtstrend noch lange nicht vorbei sein dürfte.

Laden Sie jetzt den Spezialreport kostenlos herunter und profitieren Sie von der historischen Gold-Hausse.

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.